

Special Issue

Personalized Medicine in Cardio-Oncology

Message from the Guest Editors

Several therapies have significantly increased the survival of cancer patients; however, a high risk of adverse cardiac outcomes, such as heart failure (HF) and cardiomyopathy (CM), has also been observed. Innovative anticancer therapies, such as PARP inhibitors, immune check-point inhibitors, CDK-4/6 inhibitors, and new HER-2 blocking agents, available in clinical trials and then integrated in clinical practice, have also shown cardiotoxicity effects, such as abnormalities in left ventricular function, leading to HF or CM, vasculotoxicity and metabolic diseases. The risk of severe cardiotoxicity could be higher in cancer patients already treated with standard chemotherapies, such as anthracyclines, affecting the therapeutical choices of clinicians. This Special Issue welcomes systematic reviews and communications, as well as original research, in the fields of target therapy, vasculo-toxicity, interdisciplinary health research, preclinical models, translational and clinical research, and epidemiologic research, covering the above cardio-oncology topics.

Guest Editors

Dr. Vincenzo Quagliariello


Division of Cardiology, IRCCS "G. Pascale", 80131 Naples, Italy

Dr. Stefania Cocco

Breast Unit, Istituto Nazionale Tumori- IRCCS- Fondazione G. Pascale, 80131 Napoli, Italy

Deadline for manuscript submissions

closed (15 July 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed




mdpi.com/si/109063

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).